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Abstract 
Psychiatric medications are often used in the treatment of mental disorders as well as for problem 
behaviours in people with learning disabilities. However, there is little evidence directly relating to 
people with learning disability, and most treatment decisions and experience of medication are 
based on research in the general population. Good practice demands that clinicians make every 
effort to ascertain whether the presenting complaints are those of a diagnosable mental disorder 
and that there is multidisciplinary support to ameliorate problem behaviours. 
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Introduction 
The clinical management of people with learning disability affected by mental illness often entails 
drug therapy. This is, of course, only instigated as one part of the treatment programme, in 
conjunction with the other key elements of the multimodal plan. In the management of mental 
illness among people with learning disability, the clinician is often required to address aspects of 
physical and general health, rather than primarily mental illness per se. However, this is not covered 
in the present article, which concentrates on the use of psychopharmaceutical agents. 
Principles of drug prescribing for mental illness in learning disability 
Establish psychiatric diagnosis 
Prescribing of medication for mental illness in this population should be diagnosis driven, but this is 
by no means straightforward. The diagnosis of mental illness among people with learning disability is 
a complex specialist matter, reviewed on pages 376–81 (in this issue). As emphasized throughout 
these articles on learning disability, many of the behavioural constellations encountered in clinical 
practice among people with learning disability do not constitute diagnosable mental illness. 
However, diagnosable psychiatric disorder is common among people with learning disability, and, 
where possible, the diagnosis should be the starting point in the use of pharmacological approaches 
to treatment. 
Establish cause and severity of learning disability 
The severity, or degree, of learning disability has major implications for the use of drug therapy. At a 
basic level, there is the pathoplastic effect of the severity, or degree, of learning disability on 
psychiatric disorder. This effect is mediated through the individual's cognitive level because so much 
of the expression of psychopathology is determined by overall intelligence and cognition. The more 
severely learning disabled the individual, the greater will be the divergence from more familiar 
presentations of any psychiatric disorders – and this effect operates in addition to the proneness of 
a particular condition to have its own, unique, behavioural phenotype. Standardized clinical 
assessment of the severity of learning disability and, where possible, establishment of the underlying 
cause are both prerequisites to planning for drug treatment. 
Heed the evidence base 
All prescribing of medication must be informed by the available evidence base, although the 
evidence base for use of psychopharmacological agents in people with learning disability per se is 
scant. This is principally because, for ethical reasons, few drug trials can be carried out in a 
population that includes so many people who are not capable of giving consent to such research, 
and so the evidence base for the use of psychopharmaceutical agents derives mainly from findings 
among the general population. The principal evidence base to be consulted and followed in 
prescribing for mental illness in learning disability is therefore the mainstream evidence base for 
prescribing for the diagnosis in question. This is supplemented by drug treatment studies that have 
been carried out among people with learning disability. Many of these, notably one major recent 
multicentre study, have highlighted the need for a cautious approach to prescribing.1 Most studies 
that have focused on prescribing for behaviour disorder rather than mental illness in learning 
disability have found little evidence of clear benefit of drug treatment for behaviour disorder in the 
absence of a psychiatric diagnosis. Faced with this problem, a useful consensus document has been 
developed based on the experience of UK clinicians in this area.2 
Take caution with dosage 
Here, the rules are simple – start low, go slow. For all psychopharmacological treatment of people 
with learning disability, the starting dose should be lower than for other patients; in most cases, half 
the usual dose to be recommended. This is done in order to minimize unwanted side-effects, 
particularly any sedation, movement problems, or central nervous system side-effects, all of which 
are more common among people with major developmental disabilities.3 For the same reason, 
incremental increases in dosage should be made more slowly, with the result that attaining dose for 
maximal effect is reached over twice the time-frame that applies in mainstream practice. 
Avoid polypharmacy 
It is particularly important to minimize polypharmacy in the management of mental illness among 
people with learning disability. This is important because of the prominent problems of side-effects 
in the index patient group, and also because of the difficulties inherent in discerning the positive and 
negative effects of individual drugs when given in combination – especially to people who may lack 
the ability to communicate their experience of drug effects. Not infrequently in this area of practice, 
however, the clinician will be faced with requests to use more and more medication, especially 
where there has been some initial positive effect that has subsequently apparently dissipated. In this 
common scenario, it is important to reappraise the individual's whole situation, rather than add 
additional medication. In individuals in whom polypharmacy becomes established, the clinician's first 
duty is to take a thorough drug history, from the individual as far as possible, and from key carers 
including family members. This can serve to identify issues such as the positive or negative impact of 
any medication that has been used, and drug interactions can also be identified and minimized in 
the future. 
Consider formulation 
For the most part, orthodox formulations, whether of oral or parenteral medication, will apply. 
However, especially where any compliance issues have arisen – and also where there are physical 
factors interfering with, for example, swallowing – it is occasionally necessary to explore less 
orthodox preparations or methods of administration. This may be something as simple as rendering 
the treatment more pleasurable, perhaps by attention to colour or taste. Any such considerations 
may be best worked through in close collaboration with a pharmacist. 
Optimize compliance 
More than elsewhere in psychiatric practice, much of this drug therapy will be under supervision of 
carers and/or family. The clinician must offer the relevant family/carers every possible assistance 
and support in this endeavour, for their efforts will be the main determinants of compliance. In turn, 
their efforts will be all the more determined if they are fully informed of the effects of the 
medication in question, including side-effects. This can be quite a challenge, especially where 
unwanted effects have been experienced from any previous medication used. However, only a full 
and informed account of any likely problems will be accepted now by most carers, parents, and 
families. 
Follow informed consent 
In the treatment of children with learning disabilities, consent to treatment is essentially the 
province of the parent/carer. Careful close consideration of the emergence or non-emergence of the 
capacity to consent to treatment in adulthood must be given, under the respective legislation.4,5 
Initiating drug treatment 
The decision of whether to incorporate drug treatment into a multimodal programme of 
management in clinical practice relies on a clear understanding of the nature and circumstances of 
the presenting problem. Behavioural problems that are brief, self-limiting, a reflection of inter-
current physical health problems, or due some identifiable environmental or personal stressor in the 
individual's life do not merit psychotropic medication. However, a decision to commence drug 
treatment may be sometimes taken too late, on the basis that all other avenues should be explored 
first of all. Where a diagnosable psychiatric disorder presents that has clear treatment implications, 
such as depression, the decision to adopt psychopharmacology may be taken more readily. 
Maintaining and withdrawing drug treatment 
The decisions to maintain and withdraw drug treatment should be approached with the same care 
and caution as the decisions to initiate drug treatment (Box 1). Duration of drug treatment will 
depend on various factors, including compliance, habituation and course of titration to maximal 
effect, response to treatment, occurrence of side-effects, and the natural history of the disorder 
being treated. The timescales of duration of treatment and withdrawal regimens should be 
extended, in line with the timescales for initiation and titration. 
Practice points 
•The three golden rules of prescribing in patients with learning disability and mental illness: 
○ Start low 
○ Go slow 
○ Keep the number of drugs low 
• Drug treatment of mental illness in learning disability 
○ Must be initiated as part of a wider plan 
○ Is likely to cause central nervous system side-effects 
○ Should be based on diagnosis, not behaviour 
○ Should be based on a cautious approach 
○ But ‘when in doubt, don't use drugs’ must be tempered with ‘when confident of diagnosis, do’ 
 
Box 1 
The decision to maintain or withdraw drug treatment 
• Should be made in partnership with the patient, family, and carers 
• Is dependent on the clinical response to treatment 
• Is dependent on occurrence of side-effects 
• Should follow a period of clinical recovery 
• Is informed by the natural history of the condition being treated 
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